Compositions and methods for treating alpha-1 antitrypsin deficiency
Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of α1-antitrypsin (AAT), such as seen in subjects having α1-antitrypsin deficiency (AATD), are provided.
1 . A composition comprising a guide RNA or a vector encoding the guide RNA, wherein the guide RNA comprises a guide sequence selected from SEQ ID NOs: 29 and 38 or a guide sequence that is at least 95% or 90% identical to a sequence selected from SEQ ID NOs: 29 and 38, wherein the guide RNA is a single guide RNA comprising, from 5′ to 3′, (1) the guide sequence and (2) the sequence of SEQ ID NO: 141.
2 . The composition of claim 1 , wherein the guide RNA further comprises a modification selected from:
(a) a 2′-O-methyl (2′-O-Me) modified nucleotide;
(b) a phosphorothioate (PS) bond between nucleotides;
(c) a 2′-fluoro (2′-F) modified nucleotide;
(d) a modification at one, two, three, four or five of the first five nucleotides at the 5′ end;
(e) a modification at one, two, three, four, or five of the last five nucleotides at the 3′ end;
(f) PS bonds between the first four nucleotides;
(g) PS bonds between the last four nucleotides;
(h) 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end;
(i) 2′-O-Me modified nucleotides at the last three nucleotides at the 3′ end; and
(j) a combination of two, three, four, five, six, seven, eight, or nine of (a)-(i).
3 . The composition of claim 2 , wherein the modification includes PS bonds between the first four nucleotides and/or PS bonds between the last four nucleotides.
4 . The composition of claim 2 , wherein the modification includes 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end and/or 2′-O-Me modified nucleotides at the last three nucleotides at the 3′ end.
5 . The composition of claim 1 , wherein the guide RNA is a single guide (sgRNA) comprising a scaffold sequence comprising an upper stem (US) region, wherein the guide RNA comprises 2′-O-methyl (2′-O-Me) modified nucleotides at the first three nucleotides at the 5′ end and/or 2′-O-Me modified nucleotides at the last three nucleotides at the 3′ end, and wherein each nucleotide in the US region is modified with a 2′-O-Me.
6 . The composition of claim 1 , wherein the guide RNA comprises, from 5′ to 3′ (1) the guide sequence and (2) the nucleotide sequence of GUUUUAGAmGmCmUmAmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCC GUUAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUm CmGmGmUmGmCmU*mU*mU*mU (SEQ ID NO: 408), wherein * denotes that the nucleotide is linked to the next nucleotide with a phosphorothioate (PS) bond and a lower case “m” denotes that the nucleotide is modified with 2′-O-Me.
7 . The composition of claim 1 , wherein the guide RNA comprises a sequence comprising any one of SEQ ID NOs: 130, 410-414, and 416-421, wherein each N in the sequence is collectively replaced with the guide sequence.
8 . The composition of claim 1 , wherein the composition further comprises an RNA-guided DNA binding agent or an mRNA that encodes an RNA-guided DNA binding agent, wherein the RNA-guided DNA binding agent comprises a Cas nuclease.
9 . The composition of claim 8 , wherein the Cas nuclease is a Cas cleavase.
10 . The composition of claim 8 , wherein the Cas nuclease is a Cas nickase.
11 . The composition of claim 8 , wherein the Cas nuclease is modified.
12 . The composition of claim 8 , wherein the Cas nuclease is Cas9.
13 . The composition of claim 1 , wherein the composition comprises a lipid nanoparticle (LNP) formulation.
14 . The composition of claim 13 , wherein the LNP comprises (i) an ionizable lipid; (ii) a neutral lipid; (iii) a helper lipid; and (iv) a stealth lipid.
15 . The composition of claim 14 , wherein the ionizable lipid is (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyloctadeca-9,12-dienoate.
16 . The composition of claim 13 , wherein the LNP comprises:
(i) (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate;
(ii) DSPC;
(iii) cholesterol; and
(iv) PEG-DMG.
17 . The method of claim 13 , wherein the LNP formulation comprises:
(i) about 50 mol-% (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyloctadeca-9,12-dienoate;
(ii) about 9 mol-% DSPC;
(iii) about 38 mol-% cholesterol; and
(iv) about 3 mol-% PEG-DMG.
18 . The composition of claim 1 , wherein the composition is a pharmaceutical formulation and further comprises a pharmaceutically acceptable carrier or excipient.